ACEA1021

(redirected from Licostinel)

ACEA1021

A selective antagonist at the strychnine-insensitive glycine site associated with the NMDA receptor complex which has in vivo neuroprotective effects in patients with ischaemic strokes and possibly also traumatic injury. There is currently very little clinical data to bring it forward as a therapeutic.
References in periodicals archive ?
Searle and the licostinel (ACEA 1021) program for stroke and traumatic brain injury with Novartis, which was terminated in April 1997.
In April, received back from Novartis rights to licostinel (ACEA 1021)
Nasdaq: COCN) presented new preclinical data for licostinel (ACEA 1021), its lead drug candidate for stroke, that suggests the minimum dose required for efficacy in an animal model of stroke may be three to four times lower than the doses that were well tolerated in Phase I clinical (human) infusion studies and are considerably below the doses that indicated the potential for kidney toxicity.
These animal data are encouraging because they suggest that we may reach neuroprotective levels with licostinel at doses that were well-tolerated in our earlier clinical safety studies," said Eckard Weber, M.
There was no evidence in any of the licostinel trials of the dose-limiting side effects seen with some other experimental stroke drugs _ side effects such as hallucinations, delirium, agitation, sedation and cardiovascular effects.
The company's scientists conducted a number of animal studies to carefully examine the plasma levels of licostinel necessary to demonstrate neuroprotection.
A second method to decrease the likelihood of licostinel crystals in urine is to administer the compound with probenecid.
In the animal studies, co-administration of licostinel and probenecid resulted in neuroprotection at doses below the previously determined minimum effective dose.